ArticleArthritis research & therapy2026
Differential gene expression of retrotransposons (LTR and non-LTR) in peripheral blood leukocytes of people with gout.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting ferroptosis resistance in RA fibroblast-like synoviocytes.Nature reviews. Rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo investigate the expression profiles of retrotransposons in people with gout and their clinical significance.
methodsPeripheral blood leukocytes from 92 people with gout and 22 healthy controls were analyzed using Telescope and TEspeX to quantify human endogenous retroviruses (HERVs) and non-long terminal repeat (non-LTR). Gene Set Variation Analysis (GSVA) was used to assess the association of the alterations of HERV and viral related gene panels, and xCell to evaluate the changes of immune cell subpopulations. HEK293 and THP-1 cells were treated with uric acid (UA) and monosodium urate (MSU) to explore and confirm the mechanisms of retrotransposon changes.
resultsA total of 238 HERVs and 49 non-LTR were differentially expressed in people with gout as compared to healthy controls. Notably, HERVs exhibited lower expression levels overall, whereas most non‑LTR retrotransposons showed higher expression in people with gout, suggesting distinct immunological triggers. Among 397 genes located near differentially expressed HERVs, several displayed altered expressions, indicating potential locus-specific co-regulation. GSVA revealed that gene panels related to HERV regulation, including nearby genes, KRAB zinc-finger proteins, and stemness-associated genes, were less enriched in gout patients compared to controls. xCell analysis revealed significant changes in immune cell composition, including reduced proportions of neutrophils and NK cells, and increased CD4 + memory T-cells and regulatory T cells, aligning with gout-related immune migration and modulation. Consistent with the transcriptomic data, our cell-based assays demonstrated that UA and MSU differentially modulate LTR and non-LTR retrotransposon expression across distinct cell types.
conclusionsThis study reveals a distinct and dynamic retrotransposon signature in gout, with potential implications priming, immune cell behavior, and gene regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.